vs
FATE THERAPEUTICS INC（FATE）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
FATE THERAPEUTICS INC的季度营收约是Arcadia Biosciences, Inc.的1.5倍（$1.4M vs $901.0K），Arcadia Biosciences, Inc.同比增速更快（-25.8% vs -26.4%），过去两年Arcadia Biosciences, Inc.的营收复合增速更高（-4.5% vs -15.7%）
因西斯治疗是1990年成立、总部位于亚利桑那州钱德勒的美国特色制药企业，核心产品Subsys是芬太尼的舌下含服液体制剂。芬太尼是一种见效极快的强效阿片类药物，用于缓解癌症患者爆发性疼痛，在美国，用于该适应症的芬太尼处方通常要求已有记录证明保守疗法无效。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
FATE vs RKDA — 直观对比
营收规模更大
FATE
是对方的1.5倍
$901.0K
营收增速更快
RKDA
高出0.6%
-26.4%
两年增速更快
RKDA
近两年复合增速
-15.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4M | $901.0K |
| 净利润 | — | $-1.3M |
| 毛利率 | — | 21.4% |
| 营业利润率 | — | -152.8% |
| 净利率 | — | -148.3% |
| 营收同比 | -26.4% | -25.8% |
| 净利润同比 | 37.9% | 67.1% |
| 每股收益（稀释后） | — | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FATERKDA
| Q4 25 | $1.4M | $901.0K | ||
| Q3 25 | $1.7M | $1.3M | ||
| Q2 25 | $1.9M | $1.5M | ||
| Q1 25 | $1.6M | $1.2M | ||
| Q4 24 | $1.9M | $1.2M | ||
| Q3 24 | $3.1M | $1.5M | ||
| Q2 24 | $6.8M | $1.3M | ||
| Q1 24 | $1.9M | $987.0K |
净利润FATERKDA
| Q4 25 | — | $-1.3M | ||
| Q3 25 | $-32.3M | $856.0K | ||
| Q2 25 | $-34.1M | $-4.5M | ||
| Q1 25 | $-37.6M | $2.6M | ||
| Q4 24 | — | $-4.1M | ||
| Q3 24 | $-47.7M | $-1.6M | ||
| Q2 24 | $-38.4M | $1.1M | ||
| Q1 24 | $-48.0M | $-2.4M |
毛利率FATERKDA
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 32.1% | ||
| Q2 25 | — | 43.4% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | — | 31.9% | ||
| Q3 24 | — | 32.9% | ||
| Q2 24 | — | 51.5% | ||
| Q1 24 | — | 52.3% |
营业利润率FATERKDA
| Q4 25 | — | -152.8% | ||
| Q3 25 | -1995.1% | -88.5% | ||
| Q2 25 | -1938.5% | -34.4% | ||
| Q1 25 | -2534.1% | 44.2% | ||
| Q4 24 | — | -187.7% | ||
| Q3 24 | -1703.9% | -114.5% | ||
| Q2 24 | -665.7% | — | ||
| Q1 24 | -2652.9% | -160.9% |
净利率FATERKDA
| Q4 25 | — | -148.3% | ||
| Q3 25 | -1852.4% | 65.7% | ||
| Q2 25 | -1786.6% | -306.4% | ||
| Q1 25 | -2309.5% | 216.6% | ||
| Q4 24 | — | -334.5% | ||
| Q3 24 | -1551.0% | -104.9% | ||
| Q2 24 | -567.4% | 81.2% | ||
| Q1 24 | -2493.7% | -245.5% |
每股收益（稀释后）FATERKDA
| Q4 25 | — | $-0.97 | ||
| Q3 25 | $-0.27 | $0.62 | ||
| Q2 25 | $-0.29 | $-3.26 | ||
| Q1 25 | $-0.32 | $1.90 | ||
| Q4 24 | — | $-2.99 | ||
| Q3 24 | $-0.40 | $-1.18 | ||
| Q2 24 | $-0.33 | $0.78 | ||
| Q1 24 | $-0.47 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $203.7M | $4.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $207.2M | $4.1M |
| 总资产 | $318.9M | $6.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FATERKDA
| Q4 25 | $203.7M | $4.6M | ||
| Q3 25 | $215.4M | $5.9M | ||
| Q2 25 | $222.8M | $4.4M | ||
| Q1 25 | $240.4M | $3.2M | ||
| Q4 24 | $279.1M | $4.2M | ||
| Q3 24 | $296.9M | $6.6M | ||
| Q2 24 | $304.9M | $8.1M | ||
| Q1 24 | $121.3M | $8.5M |
股东权益FATERKDA
| Q4 25 | $207.2M | $4.1M | ||
| Q3 25 | $234.1M | $5.4M | ||
| Q2 25 | $261.4M | $4.5M | ||
| Q1 25 | $288.4M | $8.9M | ||
| Q4 24 | $318.7M | $6.2M | ||
| Q3 24 | $362.3M | $10.3M | ||
| Q2 24 | $397.0M | $11.7M | ||
| Q1 24 | $426.1M | $10.6M |
总资产FATERKDA
| Q4 25 | $318.9M | $6.5M | ||
| Q3 25 | $343.7M | $8.6M | ||
| Q2 25 | $371.6M | $7.8M | ||
| Q1 25 | $398.7M | $13.0M | ||
| Q4 24 | $440.7M | $13.5M | ||
| Q3 24 | $495.0M | $15.2M | ||
| Q2 24 | $528.8M | $17.4M | ||
| Q1 24 | $569.9M | $16.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-106.1M | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | $-112.0M | — |
| 自由现金流率自由现金流/营收 | -8183.9% | — |
| 资本支出强度资本支出/营收 | 434.8% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-199.6M | — |
8季度趋势，按日历期对齐
经营现金流FATERKDA
| Q4 25 | $-106.1M | $-861.0K | ||
| Q3 25 | $-24.4M | $-257.0K | ||
| Q2 25 | $-24.6M | $-2.0M | ||
| Q1 25 | $-33.8M | $-1.6M | ||
| Q4 24 | $-122.9M | $-2.2M | ||
| Q3 24 | $-29.4M | $-1.8M | ||
| Q2 24 | $-32.3M | $-2.5M | ||
| Q1 24 | $-33.4M | $-3.2M |
自由现金流FATERKDA
| Q4 25 | $-112.0M | — | ||
| Q3 25 | $-26.6M | — | ||
| Q2 25 | $-25.9M | — | ||
| Q1 25 | $-35.0M | — | ||
| Q4 24 | $-123.6M | — | ||
| Q3 24 | $-29.9M | — | ||
| Q2 24 | $-32.4M | $-2.5M | ||
| Q1 24 | $-33.4M | $-3.2M |
自由现金流率FATERKDA
| Q4 25 | -8183.9% | — | ||
| Q3 25 | -1526.5% | — | ||
| Q2 25 | -1360.7% | — | ||
| Q1 25 | -2148.9% | — | ||
| Q4 24 | -6645.4% | — | ||
| Q3 24 | -973.1% | — | ||
| Q2 24 | -477.8% | -188.3% | ||
| Q1 24 | -1736.9% | -326.5% |
资本支出强度FATERKDA
| Q4 25 | 434.8% | 0.0% | ||
| Q3 25 | 126.5% | 0.0% | ||
| Q2 25 | 71.4% | 0.0% | ||
| Q1 25 | 73.4% | 0.0% | ||
| Q4 24 | 39.2% | 0.0% | ||
| Q3 24 | 16.1% | 0.0% | ||
| Q2 24 | 0.8% | 0.2% | ||
| Q1 24 | 4.5% | 1.3% |
现金转化率FATERKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
